Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Browsing: Multiple Myeloma
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Noa Biran, MD @HackensackUMC Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center,…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses what’s next in research for the TOUMRALINE-MM4 study. _________…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses safety concerns regarding the trial. _________ Read here:Â https://www.takeda.com/newsroom/newsreleases/2019/phase-3-trial-of-ninlaro-ixazomib-as-first-line-maintenance-therapy-met-primary-endpoint-in-multiple-myeloma-patients-not-treated-with-stem-cell-transplantation/ Â
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses whether they will be submitting to the FDA or not.
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine answers why ninlaro was compared to a placebo in TOURMALINE-MM4. Dr. Dimopoulous…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the design of the TOURMALINE-MM4 study and answers if the trail…
Meletios Athanasios Dimopoulos @thanosdimop of University Athens School of Medicine discusses the phase 3 trial of ninlaro as first line maintenance therapy…
Ajay K. Nooka, MD of @WinshipAtEmory discusses multiple myeloma disparities.
Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time…
Jesus Berdeja, MD @BerdejaJesus of Sarah Cannon Center for Blood Cancers discusses the phase 1 clinical study of bb21217.
Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.
Fredrik Schjesvold, MD of Oslo University College disucsses the ICARIA-MM study.
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
Dawn Marie Stull, PharmD of @TakedaOncology discusses closing the efficacy and effectiveness gap: outcomes in relapsed/refractory multiple myeloma (RRMM) patients…
Nizar Bahlis, MD of University of Calgary discusses patients with newly diagnosed multiple myeloma (MM) ineligible for transplant: updated analysis…
Agne Paner, MD of @RushMedical discusses updated data from the phase 2 HORIZON study. __________ Oncopeptides AB (Nasdaq Stockholm: ONCO)…
Nikhil Munshi of @DanaFarber discusses the phase I study evaluating interleukin-15 (IL-15) receptor agonist, NKTR-255 in MM and NHL.
Dennis Cooper, MD of @RutgersCancer provides detail on his upcoming presentation at ASH about clinical data on REGN5458
Zsuzsanna Devecseri, MD of @SanofiGenzyme @sanofi discusses the pivotal Phase 3 ICARIA-MM trial of isatuximab, an investigational anti-CD38 monoclonal antibody,…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Deepu Madduri, MD @DMadduri of @MountSinaiNYC @IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session…
– Results Demonstrated Statistically Significant Improvement in Progression-Free Survival – – Data to be Submitted for Presentation at an Upcoming…
Ajai Chari, MD of @MountSinaiNYC answers how the phase 2 PLEIADES study affects treatment and clinicians today. ____________ About the…
Ajai Chari, MD of @MountSinaiNYC explains a common question asked by colleagues regarding the PLEIADES study: how long do you…
Ajai Chari, MD of @MountSinaiNYC discusses the phase 2 PLEIADES study. _________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment…
Shaji Kumar, MD of Mayo Clinic explains how patient volumes associated with longer survival in MM will affect clinicians and…
Shaji Kumar, MD of Mayo Clinic explains a new study that supports higher patient volumes are associated with longer survival…
Peter Voorhees, MD of Levine Cancer Institute addresses phase 2 GRIFFIN study affecting clinicians and treatment today. _______ The Janssen…
Peter Voorhees, MD of Levine Cancer Institute answers questions received from the audience at IMW 2019 regarding the phase 2…
Peter Voorhees, MD of Levine Cancer Institute answers commonly asked questions by colleagues regarding the phase 2 GRIFFIN study: should…
Peter Voorhees, MD of Levine Cancer Institute explains how the phase 2 GRIFFIN study shows a high response rate in…
Ashley T. Freeman, MD of BC Cancer explains how the idea that higher patient volumes are associated with longer survival…
Ashley T. Freeman, MD of BC Cancer explains commonly asked questions by colleagues: why do myeloma patients seem to do…
Ashley T. Freeman, MD of BC Cancer provides insight on a study in JNCCN that supports the idea that higher…
First Phase 3 Study Combining KYPROLIS and DARZALEX, Two Critical Mechanisms of Action in Treatment of Multiple Myeloma  THOUSAND…
New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers. PLYMOUTH MEETING,…
      Phase 2 GRIFFIN study presented at 17th IMW meeting is the fourth randomized study to investigate the clinical…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Saad Usmani, MD, Chief, Plasma Cell Disorders Program, Hematologic Malignancies, Levine Cancer Institute/Atrium Health, UNC Chapel Hill School of Medicine…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the promise of bispecific antibodies in multiple myeloma…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the different combinations that are available and still…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains maintenance regimens for multiple myeloma (MM) patients.
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers discusses the outcomes from the ECOD trial in smoldering…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether…
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers explains the significance of the prolonged progression-free survival in…
Paul Richardson, MD, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma, Institute Physician, Harvard Medical School describes…